Yuhan Corporation benefits from growing overseas demand

Published: 2004-09-24 07:00:00

Updated: 2004-09-24 07:00:00

Despite its voluntary withdrawal of a popular brand Contac 600 containing controversial phenylpropanolamine (PPA) from the market in August, Yuhan Corporation said its stocks have risen 20.5 percent in the third quarter, significantly outperforming the broader benchmark KOSPI.

Amid the sluggis...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK